Prostate cancer Posts - Page 2 of 80 on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Posted by on Mar 5, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of rezvilutamide (Ariane) versus bicalutamide (Casodex) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that rezvilutamide in combination with ADT significantly improved the...

Read More

Evaluating the effects of olaparib plus abiraterone regarding patient-reported outcomes in patients with metastatic castration-resistant prostate cancer patients

Evaluating the effects of olaparib plus abiraterone regarding patient-reported outcomes in patients with metastatic castration-resistant prostate cancer patients

Posted by on Nov 22, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effects on patient-reported outcomes (PROs) of using olaparib (Lynparza) plus abiraterone (Zytiga) versus placebo plus abiraterone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The study found that adding olaparib to abiraterone in these patients did not...

Read More

Comparing the effectiveness and safety of prostate-only versus pelvic radiotherapy for patients with prostate cancer spread to nearby lymph nodes.

Comparing the effectiveness and safety of prostate-only versus pelvic radiotherapy for patients with prostate cancer spread to nearby lymph nodes.

Posted by on Oct 16, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of whole-pelvis radiotherapy (WPRT) and prostate-only radiotherapy (PORT) in patients with node-positive prostate cancer (PC) (PC that has spread to nearby lymph nodes). The study found that WPRT improves survival without relapse in these patients, with more short-term...

Read More

Evaluating the effectiveness of adding short-term androgen deprivation therapy with or without pelvic lymph node treatment to prostate bed salvage radiotherapy in patients with resected prostate cancer.

Evaluating the effectiveness of adding short-term androgen deprivation therapy with or without pelvic lymph node treatment to prostate bed salvage radiotherapy in patients with resected prostate cancer.

Posted by on Oct 7, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding short-term androgen deprivation therapy (ADT) with or without pelvic lymph node radiotherapy (PLNRT) to prostate bed salvage radiotherapy (PBRT) after surgery in patients with prostate cancer (PC). The study found that adding short-term ADT and PLNRT to PBRT significantly improved...

Read More

Evaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.

Evaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.

Posted by on Sep 27, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the benefits of radiation therapy (RT) dose escalation and the addition of short-term (ST) or long-term (LT) androgen deprivation therapy (ADT) to RT in men with localized prostate cancer (PCa). The data showed that the addition of ST or LT-ADT to RT improved survival without metastasis in these patients,...

Read More

Evaluating the long-term outcomes of radiotherapy added to standard therapy for men with metastatic prostate cancer.

Evaluating the long-term outcomes of radiotherapy added to standard therapy for men with metastatic prostate cancer.

Posted by on Sep 18, 2022 in Prostate cancer | 0 comments

In a nutshell The study investigated whether radiotherapy (RT) addedd to standard of care (SOC) treatment would be beneficial for men with metastatic (spread) prostate cancer (mPC). The study showed that adding RT to SOC improved the survival of men with low burden (defined as fewer than 10 lesions, no greater than 3cm in diameter) mPC. Some...

Read More

Evaluating the bone mineral density screening rates and their association with fracture rates among older men with prostate cancer receiving androgen deprivation therapy.

Evaluating the bone mineral density screening rates and their association with fracture rates among older men with prostate cancer receiving androgen deprivation therapy.

Posted by on Sep 17, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the bone mineral density (BMD) screening rates and their association with fracture rates among older men with prostate cancer (PC) receiving androgen deprivation therapy (ADT). The data showed that BMD screening is associated with a lower major fracture risk in these patients. Some background Prostate...

Read More

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by on Sep 1, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...

Read More

Evaluating depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormone therapy

Evaluating depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormone therapy

Posted by on Sep 1, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormonal therapy such as androgen deprivation therapy (ADT). The data showed that almost half of the patients with prostate cancer receiving ADT diagnosed with depression do not receive a documented mental health...

Read More

Evaluating the benefits of adding androgen deprivation therapy to radiation therapy and extending its duration in men with localized prostate cancer.

Evaluating the benefits of adding androgen deprivation therapy to radiation therapy and extending its duration in men with localized prostate cancer.

Posted by on Aug 14, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT) and the benefit of extending the duration of ADT in men with localized prostate cancer (PCa). The data showed that the addition of ADT to RT and extending the duration of ADT administered after RT significantly improved the survival...

Read More

Evaluating the effects of olaparib on pain and the health-related quality of life in patients with metastatic castration-resistant prostate cancer.

Evaluating the effects of olaparib on pain and the health-related quality of life in patients with metastatic castration-resistant prostate cancer.

Posted by on Aug 8, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effects of olaparib (Lynparza) on pain and the health-related quality of life (HR-QoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations (genetic abnormalities) in DNA repair genes. The data showed that treatment with olaparib was associated with a reduction in pain and...

Read More

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

Posted by on Jul 16, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) and docetaxel (Taxotere) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that darolutamide in combination with ADT and docetaxel significantly improved the overall...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor